The price of progress: Funding and financing Alzheimer's disease drug development
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Introduction: Advancing research and treatment for Alzheimer's disease (AD) and the search for effective treatments depend on a complex financial ecosystem involving federal, state, industry, advocacy, venture capital, and philanthropy funding approaches. Methods: We conducted an expert review of the literature pertaining to funding and financing of translational research and drug development for AD. Results: The federal government is the largest public funder of research in AD. The National Institute on Aging, National Institute of Mental Health, National Institute of General Medical Sciences, and National Center for Advancing Translational Science all fund aspects of research in AD drug development. Non‐National Institutes of Health federal funding comes from the National Science Foundation, Veterans Administration, Food and Drug Administration, and the Center for Medicare and Medicaid Services. Academic Medical Centers host much of the federally funded basic science research and are increasingly involved in drug development. Funding of the “Valley of Death” involves philanthropy and federal funding through small business programs and private equity from seed capital, angel investors, and venture capital companies. Advocacy groups fund both basic science and clinical trials. The Alzheimer Association is the advocacy organization with the largest research support portfolio relevant to AD drug development. Pharmaceutical companies are the largest supporters of biomedical research worldwide; companies are most interested in late stage de‐risked drugs. Drugs progressing into phase II and III are candidates for pharmaceutical industry support through licensing, mergers and acquisitions, and co‐development collaborations. Discussion: Together, the funding and financing entities involved in supporting AD drug development comprise a complex, interactive, dynamic financial ecosystem. Funding source interaction is largely unstructured and available funding is insufficient to meet all demands for new therapies. Novel approaches to funding such as mega‐funds have been proposed and more integration of component parts would assist in accelerating drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 2×
“The failure rate of AD drug development is 99% [8]; the failure rate of the development of disease-modifying therapies for AD is 100%.”
BackgroundSelf-citationMonetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 2×
“AD has a greater impact on the US economy than cancer or cardiovascular disease [15]; it has a smaller NIH research budget than either of these disorders (cancer – $6.”
BackgroundEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 1×
“An example of National Institute of Mental Health-funded AD research is the Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease [39,40].”
BackgroundOn the path to 2025: understanding the Alzheimer’s disease continuum
Aisen, P. S., Cummings, J., Jack, C. R., Morris, J. C., Sperling, R., Frölich, L., Jones, R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0283-5 · Cited by 556
Self-citationAlzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348 · cited 1×
“The ADNI has been very scientifically productive and has produced publically available data relevant to calculating sample sizes needed to power clinical trials, the predictive value of biomarkers and biomarker combinations, and the relationship of biomarkers to clinical measures [20,21].”
MethodBustin, S., & Nolan, T. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12801 · Cited by 113 · cited 1×
“Protocol errors, lack of statistical rigor in data analysis, and inadequate reporting have resulted in poor reproducibility and lack of confidence in research executed in AMC laboratories [64].”
Background
Cited by
Nichols, E., Merrick, R., Hay, S. I., Himali, D., Himali, J. J., Hunter, S., Keage, H. A. D., Latimer, C. S., Scott, M. R., Steinmetz, J. D., et al. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00019-3 · Cited by 108
Alzheimer's disease digital biomarkers multidimensional landscape and AI model scoping review
Qi, W., Zhu, X., Wang, B., Shi, Y., Dong, C., Shen, S., Li, J., Zhang, K., He, Y., Zhao, M., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01640-z · Cited by 78
Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease
Maggiore, A., Casale, A. M., Toscanelli, W., Cappucci, U., Rotili, D., Grieco, M., Gagné, J.-P., Poirier, G. G., d’Erme, M., & Piacentini, L. (2022) · Cells · doi:10.3390/cells11081284 · Cited by 40
“Unfortunately, despite the enormous efforts, both scientific and economic [49], only in 2021 did the US Food and Drug Administration (FDA) approve, with some concern, aducanumab, a human IgG1 anti-Aβ monoclonal antibody selective for Aβ aggregates, as the first disease-modifying treatment for AD [50].”
BackgroundUsing Alzheimer's disease blood tests to accelerate clinical trial enrollment
Schindler, S. E., Li, Y., Li, M., Despotis, A., Park, E., Vittert, L., Hamilton, B. H., Womack, K. B., Saef, B., Holtzman, D. M., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12754 · Cited by 38
A call for clinical trial globalization in Alzheimer's disease and related dementia
Llibre‐Guerra, J. J., Heavener, A., Brucki, S. M. D., Marante, J. P. D., Pintado‐Caipa, M., Chen, Y., Behrens, M. I., Hardi, A., Admirall‐Sanchez, A., Akinyemi, R., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12995 · Cited by 37
“Critical research areas to develop prior to clinical trial implementation include: (1) population-based studies on prevalence, incidence, and risk factors; (2) better characterization of the population in terms of genetic diversity and ADrelated biomarkers; (3) validation of robust and culturally -sensitive cognitive…”
Background
Metadata
- Authors
- Cummings, J., Reiber, C., & Kumar, P.
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2018-01
- Volume
- 4
- Issue
- 1
- Pages
- 330-343
- ISSN
- 2352-8737 (ISSN-L)
- OpenAlex
- W2808628286
- Cited by
- 98
- References
- 8
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The price of progress: Funding and financing Alzheimer's disease drug development. https://app.cochat.ai/papers/10.1016/j.trci.2018.04.008
- The paper
- Cummings, J., Reiber, C., & Kumar, P. (2018). The price of progress: Funding and financing Alzheimer's disease drug development. Alzheimer's & Dementia: Translational Research & Clinical Interventions. https://doi.org/10.1016/j.trci.2018.04.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.